Brit E. Rod
Bergen, 5020, Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
CD4+ T cells reactive to Epstein-Barr virus late lytic antigens are enriched in individuals with multiple sclerosis.
Journal: Science translational medicine
Published: July 15, 2026
Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis.
Journal: The New England journal of medicine
Published: July 01, 2026
Comparative effectiveness of rituximab and cladribine in relapsing-remitting multiple sclerosis: A target trial emulation.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: May 26, 2025
Non-inferiority of Rituximab versus OCrelizumab in Multiple Sclerosis (ROC-MS)-an individual participant data meta-analysis.
Journal: Multiple sclerosis and related disorders
Published: May 12, 2025
Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy.
Journal: Multiple sclerosis and related disorders
Published: June 21, 2023
Interferon β1a treatment does not influence serum Epstein-Barr virus antibodies in patients with multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: December 19, 2022
Breastfeeding and treatment for multiple sclerosis.
Journal: Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke
Published: October 26, 2022
Safety of breast feeding during rituximab treatment in multiple sclerosis.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: May 04, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026